Morgan Stanley Maintains Underweight on Avanos Medical, Raises Price Target to $26

Benzinga · 01/06/2023 13:50
Morgan Stanley analyst Drew Ranieri maintains Avanos Medical (NYSE:AVNS) with a Underweight and raises the price target from $24 to $26.